Search

Your search keyword '"Tyrinova, T. V."' showing total 32 results
Start Over Author "Tyrinova, T. V."
32 results on '"Tyrinova, T. V."'

17. Evaluation of a strategy for tumor-initiating stem cell eradication in primary human glioblastoma cultures as a model

Author

Dolgova, E. V., primary, Proskurina, A. S., additional, Potter, E. A., additional, Tyrinova, T. V., additional, Taranov, O. S., additional, Efremov, Ya. R., additional, Orishchenko, K. E., additional, Mishinov, S. V., additional, Stupak, V. V., additional, Ostanin, A. A., additional, Chernykh, E. R., additional, and Bogachev, S. S., additional

Published
2018
Full Text
View/download PDF

18. ROLE OF TNFα/TNF-R1-SIGNALING PATHWAY IN CYTOTOXIC ACTIVITY OF DENDRITIC CELLS AGAINST GLIOBLASTOMA CELL LINES

Author

Tyrinova, T. V., primary, Mishinov, S. V., additional, Leplina, O. Yu., additional, Alshevskaya, A. A., additional, Kurochkina, Yu. D., additional, Oleynik, E. A., additional, Kalinovskiy, А. V., additional, Lopatnikova, Yu. A., additional, Chernov, S. V., additional, Stupak, V. V., additional, Sennikov, S. V., additional, Ostanin, A. A., additional, and Chernykh, E. R., additional

Published
2018
Full Text
View/download PDF

25. Cytotoxic Activity of Interferon Alpha Induced Dendritic Cells as a Biomarker of Glioblastoma.

Author

Mishinov, S. V., Stupak, V. V., Tyrinova, T. V., Leplina, O. Yu., Ostanin, A. A., and Chernykh, E. R.

Subjects
GLIOBLASTOMA multiforme treatment, CYTOTOXIC T cells, INTERFERONS, DENDRITIC cells, BIOMARKERS, ANTIGEN presenting cells, ANTINEOPLASTIC agents
Abstract

Dendritic cells (DCs) are the most potent antigen presenting cells that can play direct role in anti-tumor immune response as killer cells. DC tumoricidal activity can be stimulated greatly by type I IFN (IFNα and IFNβ). In the present study, we examined cytostatic and cytotoxic activity of monocyte-derived IFNα-induced DCs generated from patients with brain glioma and evaluated the potential use of these parameters in diagnostics of high-grade gliomas. Herein, we demonstrated that patient DCs do not possess the ability to inhibit the growth of tumor HEp-2 cell line but low-grade and high-grade glioma patients do not differ significantly in DC cytostatic activity. However, glioma patient DCs are characterized by reduced cytotoxic activity against HEp-2 cells. The impairment of DC cytotoxic function is observed mainly in glioblastoma patients. The cytotoxic activity of DCs against HEp-2 cells below 9% is an informative marker for glioblastomas. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

31. Phosphate-modif ied CpG oligonucleotides induce in vitro maturation of human myeloid dendritic cells.

Author

Ostanin AA, Leplina OY, Burakova EA, Tyrinova TV, Fokina AA, Proskurina AS, Bogachev SS, Stetsenko DA, and Chernykh ER

Abstract

Myeloid dendritic cells (DCs) play an important role in the immune response; therefore, the search for compounds that can effectively activate DCs is a needful goal. This study was aimed to investigate the effect of synthetic CpG oligodeoxynucleotides (CpG-ODN) on the maturation and allostimulatory activity of myeloid DCs in comparison with other PAMP and DAMP molecules. For the research, we synthesized known CpG-ODN class C (SD-101 and D-SL03) containing thiophosphate internucleotide groups, and their original phosphate-modified analogues (SD-101M and D- SL03M) with mesylphosphoramide internucleotide groups (M = μ-modification). The effects of CpG-ODN and other activators were evaluated on DCs generated from blood monocytes in the presence of GM-CSF and IFN-α (IFN-DC) or IL-4 (IL4-DC). Evaluation of the intracellular TLR-9 expression showed that both types of DCs (IFN-DC and IL4-DC) contained on average 52 and 80 % of TLR-9-positive cells, respectively. The CpG-ODNs studied enhanced the allostimulatory activity of IFN-DCs, and the effect of μ-modified CpG-ODNs was higher than that of CpG-ODNs with thiophosphate groups. The stimulating effect of CpG-ODN at a dose of 1.0 μg/ml was comparable (for D-SL03, D-SL03M, SD-101) with or exceeded (for SD-101M) the effect of LPS at a dose of 10 μg/ml. At the same time, IFN-DCs were characterized by greater sensitivity to the action of CpG-ODNs than IL4-DCs. The enhancement of DC allostimulatory activity in the presence of CpG-ODNs was associated with the induction of final DC maturation, which was confirmed by a significant decrease in the number of CD14+DC, an increase in mature CD83+DC and a trend towards an increase in CD86+DC. Interestingly, the characteristic ability of LPS to enhance the expression of the co-stimulatory molecule OX40L on DCs was revealed only for the μ-analogue SD-101M. In addition, CpG-ODNs (SD-101 and SD-101M) had a stimulatory effect on IFN-γ production comparable to the action of LPS. The data obtained indicate a stimulating effect of CpG-ODN on the maturation and allostimulatory activity of human myeloid DCs, which is more pronounced for μ-modified analogs., (Copyright © AUTHORS.)

Published
2020
Full Text
View/download PDF

32. Autologous and Pooled Tumor Lysates in Combined Immunotherapy of Patients with Glioblastoma.

Author

Mishinov SV, Budnik AY, Stupak VV, Leplina OY, Tyrinova TV, Ostanin AA, and Chernykh ER

Abstract

Although major progress has been made in the standard treatment for glioblastomas, encompassing the maximal surgical resection, chemotherapy and radiation therapy, it is possible to increase survival rates significantly only in a few patients. Therefore, it is necessary to explore new therapeutic modalities, one of which is immunotherapy. The aim of the study was to evaluate the efficacy of the combined use of autologous and pooled tumor lysates in comprehensive treatment of patients with glioblastoma., Materials and Methods: All patients (n=58, including 30 males and 28 females aged 18-70 years) were randomized into three groups, two of which received immunotherapy based on injection of autologous dendritic cells pulsed with autologous tumor lysates (first protocol) or pooled lysates (second protocol) from more than one tumor, in addition to the planned standard treatment. The patients of group 3 (control) received the standard comprehensive treatment encompassing the maximum safe tumor resection followed by radiation therapy and chemotherapy., Results: The tolerability of both applied immunotherapy protocols was good: there were no anaphylactic reactions observed or patients who prematurely discontinued participation in the study. The final analysis of the data revealed no significant differences in median survival values of patients in each of the three groups. However, when analyzing the Karnofsky Performance Status in patients of group 2, it was found that it tended to improve., Conclusion: The study shows that the proposed immunotherapy protocols are safe for clinical use and have the potential to improve the patient's life quality. However, these findings should be considered intermediate until the findings of multicenter randomized clinical trials with a larger number of patients are obtained., Competing Interests: Conflict of interests. The authors have no conflict of interests to disclose.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results